Showing results (91-100 of 104) with videos related to
Sort By:
Pageof 11
Cancer Immunology, Immunotherapy : CII|December 24, 2013
Soypeptide lunasin in cytokine immunotherapy for lymphomaHua-Chen Chang, David Lewis, Chun-Yu Tung, et al.Optics Express|October 15, 2011
Monolithically integrated heterodyne optical phase-lock loop with RF XOR phase detectorRobert J Steed, Francesca Pozzi, Martyn J Fice, et al.Nature Chemical Biology|November 21, 2022
Insights into distinct signaling profiles of the µOR activated by diverse agonistsQianhui Qu, Weijiao Huang, Deniz Aydin, et al.Cell|January 15, 2019
Structure of a Signaling Cannabinoid Receptor 1-G Protein ComplexKaavya Krishna Kumar, Moran Shalev-Benami, Michael J Robertson, et al.Nature|April 14, 2022
The tethered peptide activation mechanism of adhesion GPCRsXimena Barros-Álvarez, Robert M Nwokonko, Alexander Vizurraga, et al.The Lancet. Haematology|August 28, 2020
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trialCatherine S Diefenbach, Fangxin Hong, Richard F Ambinder, et al.Neuron|September 10, 2022
Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSDCan Cao, Ximena Barros-Álvarez, Shicheng Zhang, et al.Nature Structural & Molecular Biology|June 22, 2026
Structural basis of opioid receptor activation by PCP and ketamineQianru Jiang, Jianming Han, Eve J Fine, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2007
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphomaMichael J Robertson, Brad S Kahl, Julie M Vose, et al.Blood|February 9, 2026
A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin LymphomaCatherine Diefenbach, Opeyemi Jegede, Victoria Wang, et al.Pageof 11